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a b s t r a c t
Background: Sex and blood level of sex hormones play a key role not only in the susceptibility
to develop Parkinson's disease (PD) but also inﬂuence the natural course of the disease. The
aim of this study was to compare reproductive lifespan events in females affected with PD
and in ‘‘non-parkinsonian’’ age matched subjects and to evaluate whether the whole life
endogenous oestrogen level is associated with variables describing the course of the disease.
Materials and methods: Reproductive lifespan, age at menarche, age at menopause, gynae-
cological interventions and parity were compared in 76 women with idiopathic PD and in the
age-adjusted control group of 74 subjects. Affected women underwent neurological and
psychological assessment. Data were analysed using Mann–Whitney U Test and Spearman
Rank Correlation Test.
Results: Women affected with PD had a shorter reproductive lifespan and experienced ﬁnal
menstruation earlier than the control group. Early menopause was reported by 24% of the
patients and only by 16% of the control subjects. Parkinsonian women reported more
commonly the history of surgical menopause. Duration of reproductive lifespan, age at
menopause and the type of menopause inﬂuenced both motor and cognitive functioning of
patients.
Conclusions: There may be a relationship between the lifetime average endogenous oestro-
gen level and the susceptibility to develop PD. Longer reproductive lifespan resulting in
higher ‘‘whole life’’ female sex steroids concentrations may exert a protective effect on
central nervous system, resulting in milder course of the disease.
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Parkinson's disease (PD) is a progressive neurodegenerative
disease that affects 0.15% of the general population. Cases of
PD increase steeply with advancing age and are consistently
higher in men [1]. These two facts have brought the possible
protective meaning of female sex steroids to medical atten-
tion. Oestrogens play an extremely important role in human
brain development [2]. Female sex hormones may exert their
positive effect acting via nuclear and membranous receptors,
other neurotransmitters receptors and ion channels [3].
Oestrogens may stimulate neurotrophins synthesis and
increase concentrations of antiapoptotic factors [4]. Female
sex hormones may also act as antioxidants, which have been
proven on human hipoccampal, cultured cells (HT22) [5] and
attenuate negative effects of MPTP [6]. It was also proven that
oestradiol and oestriol may avert alpha synuclein accumula-
tion as well as destabilize the already formed aggregates [7].
Apart from protective role oestrogens may directly stimulate
dopamine synthesis in the striatal cells [8].
Studies on animal models although not unanimous also
emphasize the importance of sex hormones for dopaminergic
system. The drop of endogenous hormones levels in female
monkeys after oophorectomy leads to drop in the number of
dopaminergic neurons by about 30% [9]. Sterilized rodents
treated with 17-beta oestradiol showed higher levels of
dopamine in striatum in comparison to untreated animals
[10,11].
The inﬂuence of female sex steroids in humans was broadly
discussed with regard to cognitive functioning. Higher
oestradiol levels were positively correlated with better scores
in tests assessing memory and verbal ﬂuency [12,13].
The inﬂuence of endogenous oestrogens in women
affected with Parkinson's disease is evaluated in vast
majority of cases based on analysis of reproductive life
events. The studies of Popat et al. [14], Benedetti et al. [15],
Yadav et al. [16], Nicoletti et al. [17], and Cereda et al. [18] on
age at last menstrual period, type of menopause, cumulative
length of pregnancies, use of exogenous oestrogens and its
inﬂuence on the risk of developing PD brought contradictory
results. In some studies it has been noticed that the age at
onset of PD was higher with later age at menopause and
longer reproductive lifespan [17–20], while the study of Yadav
et al. [16] draws attention to cumulative length of pregnan-
cies as a factor delaying the onset of Parkinson's disease.
Another large retrospective study involving women, who
underwent uni- or bilateral oophorectomy showed that the
risk of all types of parkinsonism was two times higher in
comparison to control subjects with no history of gynaeco-
logical interventions [21]. On the other hand the study of
Simon et al. denied any inﬂuence of surgical menopause on
the incidence of the disease irrespectively of the age of
intervention [22].
The purpose of this study was to compare reproductive life
events in women affected with Parkinson's disease and in the
age adjusted control group. We also wanted to analyse
possible correlations between reproductive lifespan events
and selected determinants of the natural course of the
disease.2. Materials and methods
Seventy-six females diagnosed with Parkinson's disease
treated in the Department of Neurology, of the Medical
University of Warsaw and in the outpatients setting were
examined. The inclusion criterion in the parkinsonian group
was diagnosis of idiopathic Parkinson's disease according to
Litvan et al. diagnostic criteria [23]. The exclusion criterion for
parkinsonian group was the presence of dementia based on
MMSE results as well as the history of surgical interventions
(pallidotomy, deep brain stimulation) as the latter could
possibly modify the natural course of the disease. The mean
age in the PD group was 63  11 years (range 42–82), mean
duration of the disease was 8  5 years (range 1–24), and with
an average age of onset being 55  12 years. Seventy-four
control subjects were randomly selected from the other
clinical wards of our hospital. Mean age in the control group
was 66  11 years (range 50–89). Only women whose records
did not contain any documentation of any form of parkinson-
ism were included to our study. Cognitively impaired females
unable to participate in the interview were excluded from the
study. Detailed medical history and the exact record of
medications use were not obtained from the patients. Those
were meaningless for the analysis of past reproductive life
events.
Protocol of the study was accepted by the Bioethical
Committee of the Medical University of Warsaw. Informed
consent was obtained from all patients.
In both groups of patients we conducted a structured
interview that contained:
- Age at menarche.
- Age at ﬁnal menstrual period.
- Type of menopause (natural vs. surgical), as surgical
menopause hysterectomy and oophorectomy were taken
together.
- Parity meaning cumulative months of pregnancies.
By subtracting the age at menopause and the age at
menarche we calculated the duration of reproductive lifespan.
All patients affected with Parkinson's disease underwent
neurological and neuropsychological examination by means
of different scales:
- Uniﬁed Parkinson's Disease Rating Scale (UPDRS) to deter-
mine motor and global functioning of the patient in ON and
in OFF stage (after 12 h withdrawal of dopaminergic
medication) [24].
- Abnormal Involuntary Movement Scale (AIMS) [25].
- Mini Mental State Examination [26].
- Beck Depression Inventory [27], Parkinson's disease Ques-
tionnaire (PDQ39) [28].
We also analysed if any of the reproductive events may
inﬂuence the determinants of the clinical course of the
disease.
Data were analysed with the Mann–Whitney U Test for
independent group comparisons and the Spearman Rank
Correlation Test for the correlation within the assessed results.
Table 1 – Reproductive lifespan characteristics in women affected with Parkinson's disease and in the control group.
Females PD (n = 76) Control group (n = 74) p
Mean  SD Range Mean  SD Range
Age 63  11 32–82 67  11 50–89 ns
FM 15  1 10–19 14  2 11–18 ns
LM 47  5 32–58 50  5 32–58 0.029
RL 33  6 16–43 36  5 18–46 0.0053
Pregnancies (months) 12  8 0–27 19  10 0–45 <0.001
FM, age at menarche; LM, age at last menstrual period; RL, reproductive lifespan; pregnancies, total length in months.
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9.0 PL). Correlation analysis data were interpreted as: 1–0.7 –
very strong correlation; 0.7–0.5 – strong correlation; 0.5–0.3
medium strength correlation; 0.3–0.1 – weak correlation –
positive or negative respectively [29].
3. Results
Reproductive life events differed signiﬁcantly in two groups.
Although the mean age at menarche was similar (15  1 in PD
vs. 14  2 in controls; p = ns), the age at last menstrual period
was markedly higher in control subjects (mean 50th year of age
vs. 47th year of age in PD patients; p = 0.029) (Table 1) 24% of the
parkinsonian patients reported menopause prior to 46th year
of age. Although menopause prior to 46th year of age was
present only in 16% of the control subjects, this difference did
not reach the statistical signiﬁcance ( p = 0.2).
The history of surgical menopause was stated by 39% of the
women affected with Parkinson's disease and only by 16% of
the women included to the control group ( p = 0.002).
Reproductive lifespan was markedly shorter in the parkin-
sonian group than in the control group, on average 33  6 years
vs. 36  5 years in control subjects ( p = 0.0053).
Cumulative months of pregnancies were higher in the
control group than in PD patients 19  10 months vs. 12  8
months in parkinsonian group ( p = 0.000015).
Amongst women affected with Parkinson's disease only 7
were in the premenopausal period at the time of examination.
None of them reported exacerbation of disease symptoms
during menstruation; they also denied ﬂuctuations associated
with menstrual cycle.
Majority of patients (77%) were diagnosed with Parkinson's
disease after menopause.
Later age at menopause and longer reproductive lifespan
were positively correlated with lower score in the motor part of
UPDRS OFF and lower stage in the Hoehn and Yahr OFF stage. It
was also positively correlated with lower scores in Beck
Depression Inventory (Table 2).Table 2 – Correlation of age at menopause (LM) and
duration of the reproductive lifespan (RL) with UPDRS,
H&Y and BDI scores.
Correlations of two parameters R-Spearman p
LM and part III UPDRS 0.30 0.01
RL and part III UPDRS 0.31 0.01
RL and BDI 0.26 0.03Type of menopause – natural vs. surgical – was also
important for the natural course of the disease. Women who
underwent gynaecological intervention reached higher scores
in the UPDRS scale state OFF in comparison to those who did
not – on average 40.8 points vs. 31.1 points ( p = 0.03). They also
presented higher score in the motor part of the UPDRS scale in
both ON and OFF state – 12 vs. 9 ( p = 0.019) and 20 vs. 10
( p = 0.005) respectively.
Women who had their last menstrual period due to natural
reasons were thus in the lower stage of Hoehn and Yahr scale
and were able to perform more activities of daily living (higher
Schwab and England scale scores) (Table 3).
Weakly expressed difference was also noticeable between
women who were diagnosed with Parkinson's disease before
menopause and those in whom the disease occurred after the
last menstrual period. Although in the ﬁrst group mentioned
mean duration of disease was markedly longer than in the
second group (10.7 vs. 7.7; p = 0.02), their global functioning
with Parkinson's disease (based on UPDRS ON and OFF scores)
was similar to women with later disease onset.
Levodopa dose (in milligrams) needed to achieve similar
therapeutic effect was markedly higher in the group affected
before the last menstrual period (1152 vs. 797; p = 0.03). Higher
levodopa intake lead to severe dyskinesias and higher AIMS
score (7.4 vs. 2.0; p = 0.03) in this group of patients. Women
affected earlier with PD reached higher PDQ39 scores in
comparison to the group with later onset of the disease, which
reﬂects worse general being (Table 4).
4. Discussion
The comparison of reproductive lifespan events in healthy
women and women affected with Parkinson's disease reveals
many differences.
Age at menopause was higher in the control group than in
the patients' group resulting in longer reproductive lifespan.
Shorter reproductive lifespan and early age at menopause
in women affected with Parkinson's disease were associated
with the fact that high percentage of patients underwent
gynaecological intervention leading to cessation of menses.
In women affected with Parkinson's disease longer dura-
tion of reproductive lifespan was positively correlated with
motor functioning. Previous studies of Cereda et al. [18],
Ragonese et al. [30] and Haaxma et al. [31] conﬁrm this ﬁnding
but also point to a relation between longer reproductive
lifespan and later age at onset of Parkinson's disease. Our
study did not reveal such correlation. Surprisingly the study by
Popat et al. [14], as well as large FRAGRAMP multicenter case
Table 3 – Comparison of the clinical course of the disease depending on the type of menopause (natural vs. surgical).
Group of patients GI (n = 29) Non-GI (n = 46) p
Mean  SD Range Mean  SD Range
UPDRS_OFF 40.3  20.8 3.0–92 31.0  15.8 7.0–71 0.03
UPDRS_ON_part III 12.4  6.7 1.0–27.0 8.9  5.9 0.0–31 0.019
UPDRS_OFF_part III 19.8  8.8 2.0–39 14.5  7.1 3.0–35 0.005
H&Y_ON 2.0  0.6 1.0–3.0 1.6  0.6 1.0–2.5 0.023
Hi_Y_OFF 2.4  0.9 1.0–4.0 1.9  0.8 1.0–4.0 0.029
SE_ON 86.9  7.1 70.0–100 91.7  7.4 70.0–100 0.005
SE_OFF 75.9  15.5 40.0–100 85.4  12.8 60.0–100 0.005
GI, women who underwent surgical menopause; non-GI, women with natural menopause.
Table 4 – Clinical parameters in women diagnosed before and after menopause.
Group Before menopause (n = 19) After menopause (n = 49) p
Mean  SD Range Mean  SD Range
Duration 10.7  5.4 1.0–21 7.7  5.2 1.0–24.0 0.02
L_DOPA 1152.6  577.5 300.0–2250 797.0  472.6 0.0–2100 0.03
AIMS 7.4  8.0 0.0–27.0 2.9  5.1 0.0–22.0 0.03
PDQ_39 56.3  23.8 9.0–94.0 41.8  19.2 8.0–76.0 0.02
AIMS/years 0.6  0.7 0.0–2.5 0.3  0.6 0.0–3.0 0.04
UPDRS_ON 22.3  10.3 7.0–48 24.8  14.0 2.0–65.0 ns
UPDRS_OFF 39.4  17.4 12.0 34.2  19.1 3.0–92.0 ns
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comes. The study by Popat et al. [14] has proven that early
menopause as well as surgical menopause decreases the risk
of developing Parkinson's disease, while the latter study points
to the possible inﬂuence of exogenous oestrogens intake as a
factor increasing the risk of developing Parkinson's disease
[17].
Although in the present study we do not deal with disease
risk, several results prove positive inﬂuence of female
endogenous sex hormones. The percentage of women in the
parkinsonian group reporting the occurrence of early meno-
pause – prior to 46th year of age – was prominently higher than
in control subjects (16%) (for Polish population average at ﬁnal
menstrual period ranges between 47th and 52nd year of age)
[32]. The cessation of menses due to surgical menopause was
also more frequent among affected women than in control
subjects. The study of Benedetti et al. [15] brought similar
results. Women affected with Parkinson's disease underwent
surgical menopause more often in comparison to control
subjects (18 vs. 7%) and the affected women reported early
ﬁnal menstrual period – prior to 46th year of age.
One of the outcomes of our study, concerning possible
protective effects of female sex hormones, might be worth
further investigation. Women diagnosed with Parkinson's
disease before menopause compared with those diagnosed
after menopause despite longer duration of the disease did not
differ when assessed with clinical scales estimating motor
functioning and cognitive impairment. On the other hand
surgical menopause causing very abrupt decrease in oestro-
gens levels was associated with much worse outcomes in the
UPDRS scale in both on and off stages.
At this point it is worth explaining why by surgical
menopause we understood all medical procedures leading
to cessation of menses – both hysterectomy and uni- orbilateral oophorectomy. It has been proven that hysterectomy
may solely impair the level of endogenous oestrogens due to
damaging blood support for the ovary. Ipso facto hysterectomy
may lead to ovarian failure in several years [33–36]. Greater risk
of developing all types of parkinsonism after uni- or bilateral
oophorectomy as well as after hysterectomy was also noted by
Rocca et al. [21].
The only similarity in reproductive life events in our study
in the two groups was the age at menarche. It is therefore
inconsistent with the ﬁnding of Martignnoni et al. [37] and
Cereda et al. [18] who found that age at menarche was
markedly higher in the parkinsonian group, compared to
healthy subjects and was positively correlated with the age at
PD onset respectively.
In the present study in a group of patients who had
Parkinson's disease diagnosed prior to the ﬁnal menstrual
period (n = 7), neither detailed medical history nor available
clinical records revealed any endocrinological abnormalities.
None of the patients reported cycle related ﬂuctuations of the
disease symptoms. The latter ﬁnding is inconsistent with
those of Quinn and Marsden [38] who pointed to marked
deterioration of parkinsonian symptoms associated with
menstruation, which could have been associated with lower
endogenous oestrogen level at this time of menstrual cycle.
Cumulative length of pregnancies was longer in the control
subjects than in the parkinsonian group. This ﬁnding is
consistent with the study of Martignnoni et al. [37] and Yadav
et al. [16]. The latter study as well as the study of Haaxma et al.
associated longer pregnancy with later onset of Parkinson's
disease, thus implying its protective mechanism [14]. Our
study does not conﬁrm this thesis. Many previous researches
point to long cumulative length of pregnancies as a possible
risk factor for developing Parkinson's disease [20,30]. Such
hypothesis arises from the fact that during pregnancy oestriol
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activity and afﬁnity to oestrogen's receptor are much weaker
than those of oestradiol [3]; however, studies on cultured cells
have proven its great potential to prevent formation of alpha
synuclein and to damage the already formed aggregates [7]. It
has also been raised that oestriol may protect from glutamate
induced excitotoxicity [39]. It is therefore worth reﬂection
whether time of pregnancy with its high oestriol and low
oestradiol level may be protective or harmful for dopaminergic
system.
5. Conclusions
Our study indicates that there may be an association between
the lifetime average oestrogen level and the susceptibility to
develop Parkinson's disease. Early menopause and shorter
reproductive lifespan can increase the risk of developing the
disease. The most harmful for functioning of the central
nervous system seems to be the surgical menopause leading to
abrupt decrease in endogenous oestrogen level. Protective
potential of endogenous oestrogens might be also conﬁrmed
by milder disease course in women diagnosed before their
ﬁnal menstrual period.
The limitation of our study is the fact that we had to assume
the whole life oestrogen level based on the reproductive life
events and not on the exact hormone levels. Perhaps the
comparison of postmenopausal sex hormones and gonado-
tropins levels might be of value. Because of difﬁculties in
interviewing demented patients this group was not included
into our study, leaving a deﬁciency, which should be further
investigated and perhaps linked to studies on oestrogen
inﬂuence on cognitive functioning.
Another limitation of our study is lack of medical records of
exogenous oestrogens intake in both groups studied. Although
only few women reported oral contraceptives/hormonal
replacement therapy use (which perhaps is unique in Polish
population), they could not remember the medications names,
which unabled the identiﬁcation of drugs components
(oestrogens/progesterone solely or mixed preparates) – there-
fore, we could not include these data into our study.
Nevertheless collecting such data in the future, as the medical
records are nowadays easier to reach could be of value.
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